Lenalidomide Pharmascience

Lenalidomide, the active ingredient in Lenalidomide Pharmascience, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with deletion 5q, and mantle cell lymphoma in adult patients, acting through anti‑angiogenic, immunomodulatory, and anti‑proliferative mechanisms.

GNH USA supplies Lenalidomide Pharmascience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product complies with EU marketing authorisation requirements and is distributed under strict quality standards.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

- Multiple myeloma: improves progression‑free survival, overall response rates, and depth of response in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces red‑cell transfusion requirements, can achieve cytogenetic remission, and prolongs overall survival in eligible patients. - Mantle cell lymphoma: contributes to disease control and prolongs remission duration in patients who have received prior lines of therapy.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Anemia: decreased red blood cell count leading to fatigue. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools that may be mild to moderate. - Rash: skin irritation or erythema. - Nausea: upset stomach and possible vomiting. - Constipation: difficulty passing stools. - Peripheral neuropathy: tingling or numbness in extremities. - Infection: increased susceptibility to bacterial or viral infections.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: significant liver enzyme elevations or liver injury. - Cardiac arrhythmias: irregular heart rhythms.

When prescribing Lenalidomide, clinicians should observe several precautionary measures to minimise risk.

- Monitor blood counts: perform regular CBC testing to detect neutropenia, thrombocytopenia, or anemia. - Assess thrombotic risk: evaluate patient history and consider prophylactic anticoagulation if risk is high. - Evaluate renal function: adjust therapy in patients with impaired kidney function. - Review concomitant medications: avoid strong CYP3A4 inhibitors that may increase exposure. - Pregnancy and lactation: contraindicated in pregnancy; ensure effective contraception and advise against breastfeeding. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide interacts with several agents; understanding the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may markedly increase lenalidomide exposure and toxicity. - Anticoagulants (warfarin, DOACs): heightened risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels and efficacy. - Immunosuppressants (e.g., cyclosporine): may increase infection risk. - Vaccines: live attenuated vaccines should be avoided due to altered immune response. - NSAIDs: may exacerbate renal toxicity when combined with lenalidomide.